CYSBIO

Their core work

CYSBIO is a Danish industrial biotech SME that engineers microbial cell factories to produce bio-based chemicals through fermentation from renewable feedstocks. Their core competence is replacing petrochemical or toxic industrial inputs with fermentation-derived alternatives — specifically sulfur-containing amino acids (cysteine, serine) and green antifouling agents for coatings. They operate at the intersection of strain engineering, bioprocess scale-up, and commercialization of sustainable chemistry. In practice, they take a target molecule, engineer a microorganism to make it at competitive cost, and bring it to industrial users in chemicals, coatings, and feed.

What they specialise in

How they've shifted over time

Both projects started in the same year (2020), so there is no true long-term evolution visible in the H2020 data — CYSBIO appears to have entered the programme already focused on fermentation-based bio-manufacturing. The visible shift within that short window is from a coatings/materials application (ZABIO, antifouling for marine and construction) toward a pure chemical-commodity play (BioBAA, amino acids as feed and chemical ingredients). The common thread across both is the cell-factory platform, suggesting they are building a multi-product fermentation company rather than a single-application specialist.

CYSBIO is moving from niche bio-based materials into higher-volume commodity biochemicals, signalling ambitions to become a broader fermentation platform company.

How they like to work

CYSBIO leads — both of its H2020 projects are SME-instrument-style coordinator roles, not partnerships within large consortia. The networks are compact (four unique partners across four countries), which fits an SME running focused Innovation Actions with a handful of supply-chain or application partners rather than broad research consortia. For a collaborator this means CYSBIO owns the IP and the roadmap; partners typically come in as technology users, scale-up support, or route-to-market.

A tight network: four distinct consortium partners spread across four countries, built around two SME-led Innovation Actions. The footprint is European rather than concentrated in any single region.

What sets them apart

CYSBIO is one of the rare Danish biotech SMEs that has convinced the EU SME Instrument to back not one but two fermentation-based product lines in the same year, and coordinates both itself. Unlike contract fermentation houses, they own the strains and the product commercialization path; unlike academic spinouts, they are already working at Innovation Action TRLs aimed at market entry. Partner with them if you want a dedicated strain-to-product operator who can actually deliver a bio-based molecule at industrial relevance, not a service provider.

Highlights from their portfolio

• BioBAA
  Their largest H2020 grant (EUR 2.06M) and the project that defines their ambition to set a new cost reference for biobased amino acids like cysteine and serine.
• ZABIO
  Applies the same cell-factory platform to an entirely different market — non-toxic antifouling for marine and construction coatings — showing cross-sector flexibility of the technology.